CHEK2 and breast carcinoma: Given the suggestion from a recent phase 2 clinical trial that CHEK2-associated breast cancers respond less well to poly-adenosine diphosphate ribose polymerase inhibitors, there is the future potential for knowledge of CHEK2 genotype to inform therapy.70